Summary
This application note explains how Gelomics Cloud connects well-level experiment design, LunaX™ device operation and structured documentation. Direct Cloud-to-device syncing removes manual re-entry, while reusable designs, protocol exports and treatment logs support reproducible 3D cell culture across runs and researchers.
What you’ll learn
- Why fragmented experiment designs, manual transcription, protocol drift and retrospective documentation undermine preclinical reproducibility.
- How Gelomics Cloud captures well-specific LunaX ECM stiffness and crosslinking parameters as defined, reusable experiment designs.
- How direct Cloud-to-device syncing removes manual re-entry between the experiment plan and the LunaX Crosslinker.
- How automated protocol exports and structured treatment logs create consistent records for review, reporting and CRO client deliverables.
- How shared team access and the Luna in-platform assistant support consistent experiment execution, troubleshooting and protocol guidance.
Key findings
- Published evidence cited in the note found that only 11% of 53 landmark preclinical oncology studies could be independently reproduced.
- Irreproducible preclinical research has been estimated to cost approximately US$28 billion annually in the United States, with cumulative prevalence exceeding 50%.
- Reported manual data-processing error rates ranged from approximately 0.29% for single-data entry to 6.57% for manual record abstraction, creating compounding risk in multi-parameter experiments.
- Gelomics Cloud records well-level matrix stiffness, crosslinking and culture parameters, then sends the confirmed design directly to the LunaX device without manual transcription.
- Reusable experiment designs, automated protocol exports and structured treatment logging support repeatable execution and a practical step towards audit-ready documentation, but do not by themselves guarantee regulatory compliance.
